CRN responded to a study published online last week in Drug Testing and Analysis, “Pharmaceutical doses of the banned stimulant oxilofrine found in dietary supplements sold in the USA,” noting that oxilofrine is not a legitimate dietary ingredient and that consumers should beware. “Oxilofrine, also referred to as methylsynephrine, has not met the legal requirements for demonstrating a reasonable expectation of safety, and thus it raises questions about the potential health risks to consumers who might use these products,” CRN President & CEO stated.

He added that not only is this patently illegal activity dangerous to consumers, but it is also damaging to upstanding dietary supplement industry companies who sell reputable products. Earlier that week, CRN commended FDA for taking action against companies breaking the law in response to the agency’s issuance of warning letters to seven companies about products listing methylsynephrine, a synonym for oxilofrene, as an ingredient. Sen. Claire McCaskill also responded to the article with a press statement and letter to FDA. “While I am pleased the FDA has moved against these manufacturers, I am alarmed by the delay between accounts of oxilofrene use in supplements and FDA action,” Sen. McCaskill observed, asking the agency to respond to eight follow-up questions and requests for information. See CRN in the News for more.

 

 

 

RETURN TO OTHER NEWSLETTER ITEMS